ClinicalTrials.gg

Program

macupatide

Also written as “LY3532226” and “Macupatide”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1, led by Eli Lilly.

Furthest: phase 2, since Nov 6, 20238 company-led studies, 4 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly84 open or runningphase 2since Nov 6, 2023Jun 9, 2021Mar 2027phase 2 · NCT07215559
  • Named in Eli Lilly’s own pipeline as Macupatide + Eloralintide, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2021First study: phase 1 study in HealthyFirst studyNCT04923269 · 41 enrolled · Singapore
  2. May 26, 2022Phase 1 study in Diabetes Mellitus, Type 2NCT05407961 · 90 enrolled · Germany
  3. May 25, 2023Phase 1 study in Diabetes Mellitus, Type 1NCT05887999 · 30 enrolled · United States
  4. Nov 6, 2023Phase 2 study in ObesityNCT06143956 · 1,481 planned · United States, Argentina
  5. Aug 14, 2024Phase 1 study in ObesityNCT06557356 · 132 enrolled · United States, Singapore
  6. Oct 9, 2025Phase 2 study in ObesityNCT07215559 · 200 enrolled · United States, Argentina, Australia and more
  7. May 11, 2026Phase 2 study in OverweightNCT07589608 · 400 planned · United States
  8. Aug 11, 2026Phase 1 study in ObesityNCT07765511 · 60 planned · Japan

Ahead

  1. Mar 2027Primary completion: phase 2 study in ObesityNCT07215559
  2. Jun 2027Primary completion: phase 1 study in ObesityNCT07765511
  3. Sep 2027Primary completion: phase 2 study in OverweightNCT07589608
  4. Sep 2027Primary completion: phase 2 study in ObesityNCT06143956

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07765511Obesity · Japan1Not yet recruitingJun 202760
NCT07589608Overweight · United States2RecruitingSep 2027400
NCT07215559Obesity · United States, Argentina, Australia and more2Active, not recruitingMar 2027200
NCT06557356Obesity · United States, Singapore1CompletedDec 12, 2025132
NCT06143956Obesity · United States, Argentina2RecruitingSep 20271,481
NCT05887999Diabetes Mellitus, Type 1 · United States1CompletedFeb 21, 202430
NCT05407961Diabetes Mellitus, Type 2 · Germany1CompletedJan 12, 202490
NCT04923269Healthy · Singapore1CompletedOct 28, 202141

How it is read

Names in the registry

  • “LY3532226”, 5 entries
  • “Macupatide”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.